CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

(JAMA Network Open) Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) ...

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Now—to the chagrin of some but not all—it has two. Transcatheter aortic valve implantation (TAVI) and transcatheter aortic valve replacement (TAVR) refer to the exact same intervention, one that has ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Cousins, MD, FACS, left, and Interventional Cardiologist Jason Schott, DO, mark the 100th transcatheter aortic valve replacement procedure performed at Memorial Health System in Marietta.

Medtronic plc’s Evolut Low-Risk trial continued to show non-inferiority of transcatheter aortic valve replacement to surgical aortic valve replacement in terms of death or disabling stroke at five ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic ...